TY  - CONF

T1  - Dupilumab is effective in children aged 6-11 years with severe atopic Dermatitis (AD) regardless of baseline serum total immunoglobulin E levels

JO  - CLINICAL AND EXPERIMENTAL ALLERGY

PY  - 2021/01/01

AU  - Cork MJ

AU  - Wollenberg A

AU  - Siegfried EC

AU  - Arkwright PD

AU  - Chen Z

AU  - Levit NA

AU  - Marco AR

AU  - Radwan A

ED  - 

VL  - 51

IS  - 12

SP  - 1659

EP  - 1659

Y2  - 2024/12/22

ER  -